Short latency afferent inhibition in Parkinson's disease patients with dementia


  • Ozlem Celebi MD,

  • Çağrı Mesut Temuçin MD, PhD,

  • Bulent Elibol MD, PhD,

  • Esen Saka MD, PhD

    Corresponding author
    1. Department of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkey
    • Department of Neurology, Hacettepe University Hospitals, 06100 Ankara, Turkey
    Search for more papers by this author

  • Relevant conflicts of interest/financial disclosures: Nothing to report. Full financial disclosures and author roles may be found in the online version of this article.



Cortical cholinergic deficiency occurs in Parkinson's disease (PD) and is more severe in PD dementia (PDD). Short-latency afferent inhibition (SAI) can be used as an in vivo test for the evaluation of the cholinergic circuit in the cerebral motor cortex.


SAI and neuropsychological profile were studied in nondemented PD, PDD, Alzheimer's disease (AD) patients, and age-matched controls.


SAI was significantly impaired in AD cases (94.7 ± 6.2 versus 55.5 ± 4.0; P < 0.0001). In PD patients, it was not different from controls (61.4 ± 5.8 versus 55.5 ± 4.0; P = 0.412). PDD cases demonstrated a significant impairment in SAI (91.4 ± 5.2 versus 55.5 ± 4.0; P < 0.0001). A high correlation was found between SAI and Mini–Mental State Examination (r = −0.68; P < 0.0001).


These findings add further evidence that differential cholinergic deficiency occurs in PD and PDD. SAI can be a neurophysiological correlate of PDD. © 2012 Movement Disorder Society